Promising results for neuropathic pain treatment

A pharmaceutical company has announced positive results from its phase Ib clinical study on its drug for neuropathic pain.

AlzeCure develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain. These latest results demonstrate that ACD440, a TRPV1 antagonist, could show positive proof-of-mechanism data, showing analgesic efficacy. The observed effects with ACD440 were highly significant over placebo. It was also well-tolerated as a topical gel on human skin, indicating suitability for further clinical development, i.e., a local treatment for neuropathic pain conditions.

Preparations are ongoing for further clinical trials with a planned Phase II trial by the end of 2021.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags